Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

Epcoritamab shows promising results in treating relapsed follicular lymphoma, with FDA priority review for a groundbreaking ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

The trial is testing epcoritamab, a biological treatment administered subcutaneously, either as a monotherapy or in combination with standard-of-care (SOC) chemotherapy agents. The goal is to ...

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Danish biotech Genmab (Nasdaq: GMAB) and US partner AbbVie (NYSE: ABBV) have reported a decisive win in a Phase III study of ...

Genmab shares were 6% higher, at $22.72 a share, after the company reported positive results of a Phase 3 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide in ...

Epcoritamab is an IgG1-bispecific antibody engineered to bind simultaneously to CD3 on T cells and CD20 on B cells, facilitating T-cell–mediated destruction of CD20+ cells. 2 It was developed ...

Epcoritamab is part of a class of drugs called bispecific T-cell engagers. In essence, epcoritamab has 2 binding epitopes, 1 to CD20, which would target malignant or normal B cells, and the other ...

Epcoritamab in combination with R 2 is being studied further in the ongoing, randomized, Phase 3 EPCORE FL-1 trial (NCT05409066). About the EPCORE® NHL-2 Trial ...